BioMarin Pharmaceutical Inc. (BMRN) Shares Sold by American Century Companies Inc

Lloyd Doyle
September 17, 2017

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Wednesday, August 2nd. Deutsche Bank maintained it with "Buy" rating and $11800 target in Thursday, July 13 report. The stock declined 0.25% or $0.23 reaching $91 per share. The stock had a trading volume of 1,764,123 shares. (NASDAQ:BMRN) earned "Equal-Weight" rating by Barclays Capital on Tuesday, November 29. It has underperformed by 11.41% the S&P500. Blackrock Management Lc reported 0% stake.

The stock increased 0.91% or $0.84 during the last trading session, reaching $92.75. About 3.48M shares traded. Universal Electronics Inc (UEIC) has risen 0.61% since September 17, 2016 and is uptrending.

On August 17 analysts at Evercore ISI Group initiated coverage with a rating of "Outperform". Therefore 72% are positive. BioMarin Pharmaceutical had 60 analyst reports since August 5, 2015 according to SRatingsIntel. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have assigned a buy rating to the stock. (NASDAQ:BMRN) earned "Perform" rating by Oppenheimer on Wednesday, November 25. On Friday, February 3 the stock rating was maintained by Benchmark with "Buy". (NASDAQ:BMRN) rating on Tuesday, August 25. The correct version of this article can be viewed at The rating was maintained by Panmure Gordon with "Buy" on Tuesday, February 2. The firm has "Buy" rating given on Wednesday, July 19 by FBR Capital.

Investors sentiment decreased to 1.04 in 2016 Q4. Its up 0.06, from 1.2 in 2016Q3. (NASDAQ:BMRN) news were published by: which released: "Citi Starts BioMarin Pharmaceutical Inc". 17 funds opened positions while 24 raised stakes. 165.79 million shares or 0.67% more from 164.68 million shares in 2016Q3 were reported. Commonwealth Bancorporation Of Aus reported 681 shares. Guggenheim Limited Liability Corporation holds 138,893 shares or 0.03% of its portfolio. Swiss National Bank now owns 631,600 shares of the biotechnology company's stock valued at $57,362,000 after purchasing an additional 22,200 shares in the last quarter. State Board Of Administration Of Florida Retirement invested in 0.03% or 444,813 shares. Arrowgrass Cap Prtnrs (Us) L P holds 178,345 shares or 0.17% of its portfolio. Institutional investors own 97.42% of the company's stock. Nationwide Fund Advsr holds 476,024 shares or 0.04% of its portfolio. BioMarin Pharmaceutical has $175 highest and $89 lowest target. (NASDAQ:BMRN) for 3,497 shares. Livforsakringsbolaget Skandia Omsesidigt has invested 0.05% of its portfolio in BioMarin Pharmaceutical Inc.

Glg Llc who had been investing in Biomarin Pharmaceutical Inc for a number of months, seems to be less bullish one the $16.11B market cap company. Victory stated it has 0.3% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 2,598 shares. Global X Management Co.

Since March 29, 2017, it had 0 buys, and 15 selling transactions for $8.25 million activity. It turned negative, as 37 investors sold GNTX shares while 145 reduced holdings. Also, EVP George Eric Davis sold 9,844 shares of the firm's stock in a transaction that occurred on Friday, June 23rd. FUCHS HENRY J had sold 15,000 shares worth $1.35 million on Friday, June 16. BIENAIME JEAN JACQUES sold $901,300 worth of stock or 10,000 shares. $862,230 worth of BioMarin Pharmaceutical Inc. Venbio Select Advisor LLC owns 500,789 shares with a value of $45,482,000. It also upped Ishares Tr (IJR) stake by 14,976 shares and now owns 38,228 shares. Novellus Sys Inc (Prn) was raised too. Cowen & Co maintained BioMarin Pharmaceutical Inc.

Several brokerages recently issued reports on BMRN. Equities analysts expect that BioMarin Pharmaceutical Inc. will post ($0.71) earnings per share for the current year. After $-0.05 actual earnings per share reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts 80.00% negative EPS growth.

Investors sentiment decreased to 0.77 in Q4 2016. 157 funds opened positions while 606 raised stakes. 234.11 million shares or 1.78% less from 238.35 million shares in 2016Q3 were reported. Hendershot Invests Inc owns 231,070 shares. 3,456 are held by Sequoia Finance Advisors Ltd Liability Co. 7,400 were reported by Lombard Odier Asset Mgmt (Switzerland). Next quarter's EPS is expected be $-0.32 with next year's EPS projected to be $-0.23. Tocqueville Asset Mngmt LP stated it has 667,450 shares or 0.17% of all its holdings.

Citigroup Inc. assumed coverage on shares of BioMarin Pharmaceutical Inc. Envestnet Asset Mgmt invested in 392,136 shares or 0.11% of the stock. The 50 day moving average went up $5.42 or +6.27% whereas the 200 day average was up by +2.62%. Moreover, Henderson Grp Plc has 0% invested in Gentex Corporation (NASDAQ:GNTX) for 15,416 shares. 2,390,386 shares of the company's stock were exchanged. Another trade for 4,000 shares valued at $303,211 was made by Canestrari Kenneth on Thursday, June 1.

Among 6 analysts covering Gentex Corp (NASDAQ:GNTX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 68% are positive. (NASDAQ:BMRN) has "Buy" rating given on Wednesday, November 18 by Goldman Sachs.

In addition to RBC Capital Markets reporting its stock price target, a total of 20 brokers have issued a research note on the company. The stock has "Outperform" rating by Robert W. Baird on Thursday, August 24. The stock of TJX Companies Inc (NYSE:TJX) has "Outperform" rating given on Wednesday, August 17 by Wedbush. BidaskClub cut BioMarin Pharmaceutical from a sell rating to a strong sell rating in a research report on Thursday, August 17th. The stock had a rise in short interest of 9.13% between July 31, 2017 and August 15, 2017.

Other reports by Iphone Fresh

Discuss This Article